TLR9 and prostate neoplasm: Vaccination of mice with a DNA vaccine encoding the ligand-binding domain of the androgen receptor, a prostate tumor associated antigen, and combined with TLR3 and TLR9 agonists, resulted in secretion of type 1 IFN from antigen-presenting cells and suppression of TRAMP-C1 prostate tumor growth [184].